Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Research and Development in Biotechnology (541711)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
T: +972-3-9241114
info@canfite.co.il
Company Contact
Can-Fite BioPharma Ltd.
10 Bareket Street, Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
Israel
Toll-Free: 800-716-4880
T: +972-3-9241114
F: +972-3-9249378
info@canfite.co.il